Affirmation of NY N316581; Tariff classification of APL-2, Pegcetacoplan (CAS # 2019171-69-6)
No Headquarters ruling in this index revokes or modifies this ruling. That is not confirmation that it is still in effect: this index does not hold every Headquarters ruling. Confirm its current status with CBP before relying on it (ruling on CBP CROSS). Text last read from CBP on Nov 21, 2026.
Key passages, quoted from the ruling
- Accordingly, by application of GRI 1, the subject APL-2 (pegcetacoplan) is properly classified in heading 3907, HTSUS, as “[p]olyacetals, other polyethers and epoxide resins, in primary forms; polycarbonates, alkyd resins, polyallyl esters and other polyesters, in primary forms.
- Specifically, the APL-2 is classified in subheading 3907.0.0000, HTSUSA which provides for polyacetals, other polyethers and epoxide resins, in primary forms; polycarbonates, alkyd resins, polyallyl esters and other polyesters, in primary forms: other polyethers.
Ruling text
This letter is in response to your correspondence, dated September 20, 2021, in which you request reconsideration of New York Ruling Letter (NY) N316581, dated July 2, 2021 (reconsideration request). NY N316581, which was issued to Apellis Pharmaceuticals, Inc. (Apellis), involves the tariff classification of APL-2, pegcetacoplan (CAS #2019171-69-6), under the Harmonized Tariff Schedule of the United States (HTSUS).
In NY N316581, U.S. Customs and Border Protection (CBP) classified the subject product under subheading 3907.20.0000, HTSUSA (Annotated) (2021), which provides for “[p]olyacetals, other polyethers and epoxide resins, in primary forms; polycarbonates, alkyd resins, polyallyl esters and other polyesters, in primary forms: other polyethers.” In your reconsideration request, you assert that the classification is incorrect, and that the pegcetacoplan is correctly classified in heading 3002, HTSUS, which provides for “[h]uman blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified” (emphasis added).
If not classified in heading 3002, HTSUS, you assert the subject merchandise is classified in heading 3003, HTSUS, which provides for “[m]edicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale.” Having reviewed NY N316581 and determined that it is correct, we hereby affirm NY N316581 for the reasons set forth below.
The product at issue was described in NY N316581, as follows: The subject product is APL-2, also referred to as pegcetacoplan (CAS # 2019171-69-6). The product is marketed for use in clinical trials to treat various immunological diseases. You state that the product targets the part of the immune system known as the complement system. The product is formed in a single reaction between Peptide 1603 and polyethylene glycol (PEG).
You note that the pegylated product is preferred because the PEG extends the half-life of the compound, allowing the APL-2 drug product to be dosed less frequently and in smaller amounts. The product will be imported into the United States as a pure bulk solid. The descriptions of the APL-2 included in your reconsideration request are consistent with those set forth above. Classification under the HTSUS is in accordance with the General Rules of Interpretation (GRIs).
GRI 1 provides that the classification of goods will be determined according to the terms of the headings of the tariff schedule and any relative section or chapter notes. In the event that the goods cannot be classified solely on the basis of GRI 1, and if the headings and legal notes do not otherwise require, the remaining GRIs 2 through 6 will then be applied in order.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (H321337).